NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
I-Mab (NASDAQ:NBP) is now covered by analysts at
Weiss Ratings. They set a "sell (d-)" rating on the stock.
I-Mab (NASDAQ:NBP) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei